Cagrisema 99% Purity Weight Loss Peptides Cagrisema (2.5mg+2.5mg) Overweight or Obesity Adults 1

Safety & Tolerability
Primary adverse events: Mild-to-moderate gastrointestinal incidents (nausea, vomiting, diarrhea; ~72.5% incidence), predominantly during dose escalation and typically transient.

No new safety signals: No clinically significant cardiovascular or neuropsychiatric adverse events observed in trials.

Dosing flexibility: Dynamic dose adjustment permitted, with lowest discontinuation rate in class (<5%).

Development Status & Research Directions
Indication focus:

Core targets: Obesity (BMI≥30) and type 2 diabetes with obesity.

Long-term cardiometabolic outcome studies (REDEFINE 3/4) expected 2025.

Competitive assessment:

Active head-to-head Phase III trial vs. tirzepatide (n=800; results 2025).

Formulation optimization:

Exploring oral (e.g., Amycretin) and monthly formulations to improve adherence.